Projects

Assessing the efficacy and outcome of treatment with rituximab in children with nephrotic syndrome

Project Description

Librexia AF is a randomized, double-blind, double-dummy, parallel group, active-controlled study to evaluate the efficacy and safety of milvexian versus apixaban in participants with atrial fibrillation. Librexia AF is a randomized, double-blind, double-dummy, parallel group, active-controlled study to evaluate the efficacy and safety of milvexian versus apixaban in participants with atrial fibrillation.Librexia AF is a randomized, double-blind, double-dummy, parallel group, active-controlled study to evaluate the efficacy and safety of milvexian versus apixaban in participants with atrial fibrillation.

Project Duration

2022 - 2023

Project Lead

Dr. Anil Vasudevan

Authors

Dr. Anil Vasudevan, Dr. Sravani M

Project Status

completed